Nektar Therapeutics (NKTR) shares were up over 16% in recent Monday trading after the company said it agreed to sell its Huntsville, Alabama, manufacturing facility and PEGylation reagent supply business to Ampersand Capital Partners for $90 million.
The consideration comprises $70 million in cash and a $20 million equity position in a newly created Ampersand portfolio company that will house the Huntsville-based facility, according to the statement.
In addition, Nektar said it will sign manufacturing supply agreements with the new Ampersand company for its PEG reagent needs.
The deal is expected to close by Dec. 2 and Nektar said it will retain all rights to current and future royalty streams and milestones related to its existing PEGylated product license deals.
Nektar Chief Executive Howard Robin said the sale streamlines the company's operations and extends its cash runway into Q4 2026.
Price: 1.43, Change: +0.20, Percent Change: +16.26
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。